Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Dr Karuna Sree P
Asst. Professor
Dept. Of Pharmacology
Kamineni Institute of Medical Sciences
 Introduction
 PPAR receptors – types
 Mechanism of action
 Role of PPARS
 Clinical significance
 Conclusion
3/23/20...
 Issemann and Green discovered Peroxisome
proliferator activated receptors (PPAR).
 The different types of PPAR initiall...
Nuclear Receptor Superfamily
Type 1
Receptors
Eg. GR, MR,
AR,ER,PR
Steroids
Type 2 Receptors
Eg. TR, VDR, RAR,
PPAR
Thyroi...
Binds to response
elements on DNA
Ligands
bind
Co-activators
Co-regulator
proteins
3/23/2015 5Dr Karuna Sree P, Dept. of P...
 Plays a central role in the regulation of
 Storage and catabolism of dietary fats and
carbohydrates
 Adipocyte differe...
Ubiquitous but predominant in
 α - Liver, kidney, heart, muscle, adipose tissue.
 β / δ - Brain, adipose tissue, and ski...
PPAR Partner Ligand
Process
affected
Related
disease process
PPAR α
Active state -
fasting
Retinoic
acid X
receptor
Fatty
...
3/23/2015 9Dr Karuna Sree P, Dept. of Pharmacology, KIMS
3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 10
 Cellular organelle
 More than 50 enzymes are present in it, among
which catalase and oxidase are important
 Role : In ...
 PPAR α agonists : Fibrates - Hyperlipidaemia
 PPAR γ agonists : Thiazolidinediones -
Hyperglycaemia
 PPAR dual agonist...
PPAR α agonists
Fibrates
3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 13
 1st generation fibrates : Clofibrate
 2nd generation : Gemfibrozil, Fenofibrate,
Bezafibrate, ciprofibrate
 Lowers VLD...
3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 15
Activates peroxisome proliferation activated
receptor factor (P...
3/23/2015
Dr Karuna Sree P, Dept. of Pharmacology, KIMS
16
Pk Dose uses
Gemfibrozil
T1/2 : 1-2hrs, High efficacy
in Type III & ↓CH, Factor
VII-PL complex & promotes
fibrinolysis
Abs...
 Uses : Hypertriglyceridaemias.
 Fenofibrate is uricosuric - given in coexisting
hyperuricaemia
 ADR : GI, skin rashes,...
PPAR γ agonists
Thiazolidinediones
(Glitazones)
3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 19
 These are insulin-sensitizing drugs
 Rosiglitazone
 Pioglitazone
 TZDs have also effects on TG, FFA, and ketone
body ...
 Because of Antiproliferative, Anti-inflammatory,
Immunomodulatory effects
 Have potential role
 In the treatment of di...
Rosiglitazone
Pioglitazone
3/23/2015 22Dr Karuna Sree P, Dept. of Pharmacology, KIMS
Activate insulin responsive genes -
r...
 Pioglitazone has no effect on LDL levels, ↓
triglyceride & ↑ HDL
 Rosiglitazone has inconsistent effect on lipid
profil...
 Absorption : Completely absorbed from GIT
 Distribution : >95% bound to plasma proteins
 Metabolism : Rosiglitazone - ...
 Pt who benefit most are type II DM with
substantial amount of insulin resistance
 Also used in PCOD
 Monotherapy – Hyp...
 Weight gain: due to fluid retention & edema
 ↑ Extracellular fluid volume
 Worsening of CHF
 ↑ Deposition of subcutan...
 Liver disease
 Congestive heart failure
 Pregnancy
 Lactating mother
 Children
3/23/2015 27Dr Karuna Sree P, Dept. o...
3/23/2015 28Dr Karuna Sree P, Dept. of Pharmacology, KIMS
 Rosiglitazone banned in India* - GSR NO. 910(E) on
12.11.2010, as well in European medicines agency
 US FDA# – in Nov 2...
 Selective PPAR Modulators gained importance
to combat the side effect profile of glitazones.
 SPPARM have partially act...
 These are termed as glitazars, several
dual PPAR-α/γ agonists have been
developed.
3/23/2015 32Dr Karuna Sree P, Dept. o...
3/23/2015 33Dr Karuna Sree P, Dept. of Pharmacology, KIMS
Drug Reasons for stopping the
trials
Ragaglitazar, MK-0767,
Naveglitazar
bladder cancer and
hyperplasia in rodent studies
...
 The first Glitazar to be approved in India-2013
 Indication : diabetic dyslipidemia or
hypertriglyceridemia in type-2 d...
 Chemical structure : aryl alkoxy propionic acid
 Strong PPAR-α effect with moderate PPAR-γ
effect
 Pk : well absorbed,...
 PPAR δ regulates fatty acid metabolism in the brain,
skeletal muscle and adipose tissue.
 Actions : improves insulin se...
3/23/2015 38Dr Karuna Sree P, Dept. of Pharmacology, KIMS
 Agonist actions on PPAR α, β/δ, γ receptors
 Being developed for type 2 diabetes and
dyslipidemia
 *Bezafibrate found ...
 Type 2 Diabetes mellitus
 Atherosclerosis, Dyslipidaemia
 Obesity
 Metabolic syndrome
 Cardiovascular diseases
 Can...
3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 41
 Inflammation & Neurology
 Alzheimers disease
 Multiple scle...
 PPARs are interesting pharmaceutical targets.
 They have multiple beneficial effects.
 New PPAR drugs showing co agoni...
 Guyton AC, Hall JE. Text book of Medical physiology. 11th ed.
Philadelphia (Pa): Saunders; 2006.
 Laurence L. Brunton, ...
3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 44
3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 45
Upcoming SlideShare
Loading in …5
×

Drugs acting on ppar

3,055 views

Published on

what are the various types of PPAR receptors, how do they act. what drugs act through PPAR recptors i.e., agonists and antagonists

Published in: Health & Medicine
  • Be the first to comment

Drugs acting on ppar

  1. 1. Dr Karuna Sree P Asst. Professor Dept. Of Pharmacology Kamineni Institute of Medical Sciences
  2. 2.  Introduction  PPAR receptors – types  Mechanism of action  Role of PPARS  Clinical significance  Conclusion 3/23/2015 2Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  3. 3.  Issemann and Green discovered Peroxisome proliferator activated receptors (PPAR).  The different types of PPAR initially identified in xenopus frog.  Belongs to nuclear receptor family. 3/23/2015 3Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  4. 4. Nuclear Receptor Superfamily Type 1 Receptors Eg. GR, MR, AR,ER,PR Steroids Type 2 Receptors Eg. TR, VDR, RAR, PPAR Thyroid hormone Vitamin D Retinoic acid Lipid derivatives Orphan receptors Ligands not known Eg. SF-1, HNF4 3/23/2015 4Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  5. 5. Binds to response elements on DNA Ligands bind Co-activators Co-regulator proteins 3/23/2015 5Dr Karuna Sree P, Dept. of Pharmacology, KIMS *Daryl K Granner. Hormone Action & SignalTransduction. In: Robert K. Murray, Daryl K. Granner, PeterA. Mayes,VictorW. Rodwell editors. Harper’s Illustrated Biochemistry. 26th ed. NewYork McGraw-Hill
  6. 6.  Plays a central role in the regulation of  Storage and catabolism of dietary fats and carbohydrates  Adipocyte differentiation  Inflammatory responses  Cancer  Types :  PPAR α  PPAR β / δ  PPAR γ 3/23/2015 6Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  7. 7. Ubiquitous but predominant in  α - Liver, kidney, heart, muscle, adipose tissue.  β / δ - Brain, adipose tissue, and skin.  γ - three forms: γ1 - Heart, muscle, colon, kidney, pancreas & spleen. γ 2 - Adipose tissue. γ 3 - Macrophages, large intestine, white adipose tissue. 3/23/2015 7Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  8. 8. PPAR Partner Ligand Process affected Related disease process PPAR α Active state - fasting Retinoic acid X receptor Fatty acids(FA) Fibrates Peroxisome proliferation Dyslipidaemia PPAR - β/δ FA Proteins Dyslipidaemia Obesity PPAR - γ Active state - fed FA,TZD Lipid & CHO metabolism Insulin resistance Obesity, Metabolic syndrome PCOS, NAFLD Cardiac steatosis 3/23/2015 8Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  9. 9. 3/23/2015 9Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  10. 10. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 10
  11. 11.  Cellular organelle  More than 50 enzymes are present in it, among which catalase and oxidase are important  Role : In the metabolism of  fatty acids and other lipids (cholesterol, bile acids)  Purines  Aminoacids  Hydrogen peroxide 3/23/2015 11Dr Karuna Sree P, Dept. of Pharmacology, KIMS *Robert K. Murray, Daryl K. Granner, PeterA. Mayes,VictorW. Rodwell. Harper’s Illustrated Biochemistry. 26th ed. NewYork McGraw-Hill.
  12. 12.  PPAR α agonists : Fibrates - Hyperlipidaemia  PPAR γ agonists : Thiazolidinediones - Hyperglycaemia  PPAR dual agonists (α ,γ) : Glitazars – Hyperlipidaemia & Hyperglycaemia  PPAR δ agonists : under investigation for obesity, cancer  PPAR pan agonists 3/23/2015 12Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  13. 13. PPAR α agonists Fibrates 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 13
  14. 14.  1st generation fibrates : Clofibrate  2nd generation : Gemfibrozil, Fenofibrate, Bezafibrate, ciprofibrate  Lowers VLDL, TG by 50% & ↑ HDL-C by 15% & ↓ fibrinogen levels & LDL-C by 15-20%  Effect mediated through PPAR∝ receptor expressed in liver, fat & muscles. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 14
  15. 15. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 15 Activates peroxisome proliferation activated receptor factor (PPAR-∝) ↓TG, VLDL & ↑ HDL ↑ fatty acid oxidation ↑ LPL activity ↑ Apo A I & II, hepatic SREBP-1 production ↓ Apo CIII
  16. 16. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 16
  17. 17. Pk Dose uses Gemfibrozil T1/2 : 1-2hrs, High efficacy in Type III & ↓CH, Factor VII-PL complex & promotes fibrinolysis Absorption : Oral - Complete Metabolism: Glucuronida tion Excretion: urine 600mg BD before meals Type III Type IV,V And as adjuvant in Type II 200mg TDS Bezafibrate Dose reduction needed in elderly / renal insufficiency ↑action of warfarin 200mg OD with mealsFenofibrate T1/2 : 20 hrs Greater ↓ in CH & ↑ HDL Most suitable combination with statins 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 17
  18. 18.  Uses : Hypertriglyceridaemias.  Fenofibrate is uricosuric - given in coexisting hyperuricaemia  ADR : GI, skin rashes, body ache, myalgia, reversible myopathy.  Eosnophilia, Impotence, Blurred Vision, cholelithiasis with Gemfibrozil  ↑ Aminotransferases & Alk. Phosphatase – Fenofibrate  DI : with statins increase myositis, potentiates affect of warfarin 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 18
  19. 19. PPAR γ agonists Thiazolidinediones (Glitazones) 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 19
  20. 20.  These are insulin-sensitizing drugs  Rosiglitazone  Pioglitazone  TZDs have also effects on TG, FFA, and ketone body level in several animal models of T2DM* 3/23/2015 20Dr Karuna Sree P, Dept. of Pharmacology, KIMS *Caring for diabetes.Treatment and prevention : Emerging therapies. Available at www.caring for diabetes.com.
  21. 21.  Because of Antiproliferative, Anti-inflammatory, Immunomodulatory effects  Have potential role  In the treatment of diabetic complications  inflammatory-proliferative diseases in non- insulin-resistant euglycaemic individuals  Autoimmune  Atopic and inflammatory diseases  sepsis and reperfusion injury. 3/23/2015 21Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  22. 22. Rosiglitazone Pioglitazone 3/23/2015 22Dr Karuna Sree P, Dept. of Pharmacology, KIMS Activate insulin responsive genes - regulate carbohydrate & lipid metabolism Sensitize the peripheral tissues to insulin ↑ Glucose transport into muscle & adipose tissue Inhibit hepatic gluconeogenesis Promote lipogenesis ↓Blood Glucose Selective agonists of PPAR - bind to the receptor
  23. 23.  Pioglitazone has no effect on LDL levels, ↓ triglyceride & ↑ HDL  Rosiglitazone has inconsistent effect on lipid profile it ↑ HDL & LDL levels  The TZDs lead to a favorable redistribution of fat from visceral to subcutaneous tissues. 3/23/2015 23Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  24. 24.  Absorption : Completely absorbed from GIT  Distribution : >95% bound to plasma proteins  Metabolism : Rosiglitazone - CYP2C8  Pioglitazone - CYP2C8 & CYP3A4  Excretion : Rosiglitazone in urine  Pioglitazone in bile  Drug interactions less with rosiglitazone 3/23/2015 24Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  25. 25.  Pt who benefit most are type II DM with substantial amount of insulin resistance  Also used in PCOD  Monotherapy – Hypoglycemia rare  Slow acting – takes 1 month for its action Dose  Pioglitazone: 15 to 45 mg once daily orally  Rosiglitazone: 4 to 8 mg once daily orally 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 25
  26. 26.  Weight gain: due to fluid retention & edema  ↑ Extracellular fluid volume  Worsening of CHF  ↑ Deposition of subcutaneous fat  Mild anemia: due to hemodilution  Hepatotoxicity : rare  Rosiglitazone: ↑risk of fractures especially in elderly women 3/23/2015 26Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  27. 27.  Liver disease  Congestive heart failure  Pregnancy  Lactating mother  Children 3/23/2015 27Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  28. 28. 3/23/2015 28Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  29. 29.  Rosiglitazone banned in India* - GSR NO. 910(E) on 12.11.2010, as well in European medicines agency  US FDA# – in Nov 2013 removed the warnings/ restrictions on Rosiglitazone initially put in 2010 for causing heart failure.  Pioglitazone : Banned in India & reintroduced- 2011.  ^US FDA drug safety communication recommend –  Not to use / use with caution in patients with active / prior h/o bladder cancer 3/23/2015 29Dr Karuna Sree P, Dept. of Pharmacology, KIMS *www.cdsco.nic.in/writereaddata/prohibition_rosiglitazone.pdf #http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand Providers/ucm376365.htm ^http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm
  30. 30.  Selective PPAR Modulators gained importance to combat the side effect profile of glitazones.  SPPARM have partially activated PPARγ target genes involved in adipogenesis and more agonistic activity on target genes influencing insulin sensitivity.  INT131, MBX-102, antihypertensive drug - Telmisartan 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 30
  31. 31.  These are termed as glitazars, several dual PPAR-α/γ agonists have been developed. 3/23/2015 32Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  32. 32. 3/23/2015 33Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  33. 33. Drug Reasons for stopping the trials Ragaglitazar, MK-0767, Naveglitazar bladder cancer and hyperplasia in rodent studies Tesaglitazar renal dysfunction Muraglitazar – completed phase III studies increased risk of death, myocardial infarction, or stroke when compared with patients who received either pioglitazone or placebo. Aliglitazar Side effect proflie on kidneys and heart 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 34
  34. 34.  The first Glitazar to be approved in India-2013  Indication : diabetic dyslipidemia or hypertriglyceridemia in type-2 diabetes not controlled by statins alone. Development of saroglitazar 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 35
  35. 35.  Chemical structure : aryl alkoxy propionic acid  Strong PPAR-α effect with moderate PPAR-γ effect  Pk : well absorbed, nearly 96% plasma protein bound, metabolism by oxidation & excreted in bile  Dose : 4mg oral tablet OD  Adverse effects : gastritis, asthenia and pyrexia 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 36
  36. 36.  PPAR δ regulates fatty acid metabolism in the brain, skeletal muscle and adipose tissue.  Actions : improves insulin sensitivity and ↑HDL in T2DM, dyslipidemia & obesity.  Cancer  Atherosclerosis  Enhance oligodendrocyte maturation and differentiation & regulates myelination of neurons  Drugs under development for treating obesity, cancer, Infertility  GW501516  GW0742 3/23/2015 37Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  37. 37. 3/23/2015 38Dr Karuna Sree P, Dept. of Pharmacology, KIMS
  38. 38.  Agonist actions on PPAR α, β/δ, γ receptors  Being developed for type 2 diabetes and dyslipidemia  *Bezafibrate found to have pan agonist action 3/23/2015 39Dr Karuna Sree P, Dept. of Pharmacology, KIMS *Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005 ;16:4-14.
  39. 39.  Type 2 Diabetes mellitus  Atherosclerosis, Dyslipidaemia  Obesity  Metabolic syndrome  Cardiovascular diseases  Cancers – colon, breast, prostate, lung, blood  Assisted reproductive technology, PCOS  Retinopathy  Viral infections 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 40
  40. 40. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 41  Inflammation & Neurology  Alzheimers disease  Multiple sclerosis  Parkinson's disease  Ischemic stroke  Spinal cord Injury  Psoriatic arthritis  Chronic obstructive pulmonary disease / Br. Asthma  Inflammatory bowel disease  Rheumatoid arthritis
  41. 41.  PPARs are interesting pharmaceutical targets.  They have multiple beneficial effects.  New PPAR drugs showing co agonism or pan- agonism are expected to show synergistic effects on various metabolic and inflammatory diseases.  Long-term trials are needed to evaluate the efficacy and safety of these wonder agents. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 42
  42. 42.  Guyton AC, Hall JE. Text book of Medical physiology. 11th ed. Philadelphia (Pa): Saunders; 2006.  Laurence L. Brunton, Keith L. Parker, editors. Textbook of Goodman and Gillman’s Manual of Pharmacology and therapeutics, 12th ed. New York:Mac Graw Hill’s Companies;2010.  Kumar A, Hasamnis A. A clinical update on peroxisome proliferator- activated receptors. Syst Rev Pharm 2010;1:175-81.  V. A. Javiya, J. A. Patel. The role of peroxisome proliferator – activated receptors in human disease. Indian J Pharmacol 2006;38:243-53  Taygerly JP, McGee LR, Rubenstein SM, Houze JB, Cushing TD, Li Y. Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity. Bioorg Med Chem 2013;21:979-92. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 43
  43. 43. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 44
  44. 44. 3/23/2015 Dr Karuna Sree P, Dept. of Pharmacology, KIMS 45

×